派格生物医药-B今日盘中股价大跌6.96%，引起了市场的关注。
消息面上，该股此前因与腾瑞制药就GLP-1类药物派达康达成中国大陆独家商业化合作，股价在前期经历了连续大幅拉升，短期累计涨幅显著。经历暴涨后，当前成交额较前期明显萎缩，股价出现技术性回调。
根据合作协议，双方确立了累计销售规模超人民币100亿元的核心商业化目标，腾瑞制药将支付合计约1.4亿港币权益金，派达康近期将在方舟健客互联网医院平台全网首发。尽管同期生物科技板块整体表现偏强，但该股在获利了结压力下逆市下跌。
派格生物医药-B今日盘中股价大跌6.96%，引起了市场的关注。
消息面上，该股此前因与腾瑞制药就GLP-1类药物派达康达成中国大陆独家商业化合作，股价在前期经历了连续大幅拉升，短期累计涨幅显著。经历暴涨后，当前成交额较前期明显萎缩，股价出现技术性回调。
根据合作协议，双方确立了累计销售规模超人民币100亿元的核心商业化目标，腾瑞制药将支付合计约1.4亿港币权益金，派达康近期将在方舟健客互联网医院平台全网首发。尽管同期生物科技板块整体表现偏强，但该股在获利了结压力下逆市下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.